431 related articles for article (PubMed ID: 8957644)
21. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions.
Rzany B; Correia O; Kelly JP; Naldi L; Auquier A; Stern R
Lancet; 1999 Jun; 353(9171):2190-4. PubMed ID: 10392983
[TBL] [Abstract][Full Text] [Related]
22. A retrospective, 5-year, clinicoepidemiological study of severe cutaneous adverse reactions (SCARs).
Singh GK; Mitra B; Arora S; Akhoon N; Verma R; Sharma P; Mitra D
Int J Dermatol; 2021 May; 60(5):579-588. PubMed ID: 33454956
[TBL] [Abstract][Full Text] [Related]
23. Severe cutaneous adverse reactions associated with the immune checkpoint inhibitors: A case/non-case analysis using the Food and Drug Administration Adverse Event Reporting System.
Godfrey H; Jedlowski P; Thiede R
Australas J Dermatol; 2024 May; 65(3):243-253. PubMed ID: 38572842
[TBL] [Abstract][Full Text] [Related]
24. Bullous fixed drug eruption masquerading as recurrent Stevens Johnson syndrome.
Dharamsi FM; Michener MD; Dharamsi JW
J Emerg Med; 2015 May; 48(5):551-4. PubMed ID: 25433836
[TBL] [Abstract][Full Text] [Related]
25. Severe delayed skin reactions related to drugs in the paediatric age group: A review of the subject by way of three cases (Stevens-Johnson syndrome, toxic epidermal necrolysis and DRESS).
Belver MT; Michavila A; Bobolea I; Feito M; Bellón T; Quirce S
Allergol Immunopathol (Madr); 2016; 44(1):83-95. PubMed ID: 26089185
[TBL] [Abstract][Full Text] [Related]
26. Stevens-Johnson syndrome and toxic epidermal necrolysis-challenges of recognition and management.
Sane SP; Bhatt AD
J Assoc Physicians India; 2000 Oct; 48(10):999-1003. PubMed ID: 11200928
[TBL] [Abstract][Full Text] [Related]
27. [Severe cutaneous adverse drug reactions. Clinical features and epidemiology ].
Mockenhaupt M
Hautarzt; 2005 Jan; 56(1):24-31. PubMed ID: 15625600
[TBL] [Abstract][Full Text] [Related]
28. Cutaneous adverse reactions to valdecoxib distinct from Stevens-Johnson syndrome and toxic epidermal necrolysis.
Ziemer M; Wiesend CL; Vetter R; Weiss J; Blaschke S; Norgauer J; Mockenhaupt M
Arch Dermatol; 2007 Jun; 143(6):711-6. PubMed ID: 17576936
[TBL] [Abstract][Full Text] [Related]
29. Distinguishing Stevens-Johnson syndrome/toxic epidermal necrolysis from clinical mimickers during inpatient dermatologic consultation-A retrospective chart review.
Weinkle A; Pettit C; Jani A; Keller J; Lu Y; Malachowski S; Trinidad JC; Kaffenberger BH; Ergen EN; Hughey LC; Smith D; Seminario-Vidal L
J Am Acad Dermatol; 2019 Sep; 81(3):749-757. PubMed ID: 31150704
[TBL] [Abstract][Full Text] [Related]
30. Differential diagnosis of severe cutaneous drug eruptions.
Bachot N; Roujeau JC
Am J Clin Dermatol; 2003; 4(8):561-72. PubMed ID: 12862499
[TBL] [Abstract][Full Text] [Related]
31. A patch testing and cross-sensitivity study of carbamazepine-induced severe cutaneous adverse drug reactions.
Lin YT; Chang YC; Hui RC; Yang CH; Ho HC; Hung SI; Chung WH
J Eur Acad Dermatol Venereol; 2013 Mar; 27(3):356-64. PubMed ID: 22211830
[TBL] [Abstract][Full Text] [Related]
32. Epidemiology of cutaneous adverse drug reactions.
Mockenhaupt M
Chem Immunol Allergy; 2012; 97():1-17. PubMed ID: 22613850
[TBL] [Abstract][Full Text] [Related]
33. Agreement Among Different Scales for Causality Assessment in Drug-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.
Sivagourounadin K; Rajendran P; Selvarajan S; Ganesapandian M
Curr Drug Saf; 2022; 17(1):40-46. PubMed ID: 34126908
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic patch testing following tuberculosis-associated cutaneous adverse drug reactions induces systemic reactions in HIV-infected persons.
Lehloenya RJ; Todd G; Wallace J; Ngwanya MR; Muloiwa R; Dheda K
Br J Dermatol; 2016 Jul; 175(1):150-6. PubMed ID: 26918554
[TBL] [Abstract][Full Text] [Related]
35. Review of culprit drugs associated with patients admitted to the burn unit with the diagnosis of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Syndrome.
de Bustros P; Baldea A; Sanford A; Joyce C; Adams W; Bouchard C
Burns; 2022 Nov; 48(7):1561-1573. PubMed ID: 34924230
[TBL] [Abstract][Full Text] [Related]
36. A 10-years retrospective study on Severe Cutaneous Adverse Reactions (SCARs) in a tertiary hospital in Penang, Malaysia.
Loo CH; Tan WC; Khor YH; Chan LC
Med J Malaysia; 2018 Apr; 73(2):73-77. PubMed ID: 29703869
[TBL] [Abstract][Full Text] [Related]
37. Incidence, causative factors and mortality rates of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in northern Italy: data from the REACT registry.
Diphoorn J; Cazzaniga S; Gamba C; Schroeder J; Citterio A; Rivolta AL; Vighi GD; Naldi L;
Pharmacoepidemiol Drug Saf; 2016 Feb; 25(2):196-203. PubMed ID: 26687641
[TBL] [Abstract][Full Text] [Related]
38. Clinical features and prognostic factors of severe cutaneous adverse drug reactions: A single-center retrospective study of 209 cases in China.
Deng M; Su Y; Wu R; Li S; Tang G; Kuang Q; Luo X; Zhu Y; Shen W
Int Immunopharmacol; 2023 Jan; 114():109530. PubMed ID: 36508915
[TBL] [Abstract][Full Text] [Related]
39. Severe cutaneous adverse reactions in a local hospital setting: a 5-year retrospective study.
Su P; Aw CW
Int J Dermatol; 2014 Nov; 53(11):1339-45. PubMed ID: 25070588
[TBL] [Abstract][Full Text] [Related]
40. Recognition and Management of Severe Cutaneous Adverse Drug Reactions (Including Drug Reaction with Eosinophilia and Systemic Symptoms, Stevens-Johnson Syndrome, and Toxic Epidermal Necrolysis).
Owen CE; Jones JM
Med Clin North Am; 2021 Jul; 105(4):577-597. PubMed ID: 34059239
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
